Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 18 | 2025 | 1159 | 3.970 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 167 | 3.210 |
Why?
|
| Diabetes Mellitus | 8 | 2024 | 390 | 1.940 |
Why?
|
| Dyslipidemias | 5 | 2023 | 60 | 1.940 |
Why?
|
| Hypertension | 10 | 2026 | 983 | 1.940 |
Why?
|
| Practice Guidelines as Topic | 10 | 2018 | 395 | 1.670 |
Why?
|
| Risk Assessment | 13 | 2025 | 1423 | 1.570 |
Why?
|
| Telemedicine | 2 | 2026 | 122 | 1.550 |
Why?
|
| Heart Failure | 7 | 2024 | 728 | 1.520 |
Why?
|
| Troponin T | 4 | 2019 | 92 | 1.520 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 2019 | 10 | 1.460 |
Why?
|
| United States | 26 | 2025 | 4077 | 1.330 |
Why?
|
| Myocardial Infarction | 8 | 2024 | 466 | 1.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 316 | 1.220 |
Why?
|
| Middle Aged | 35 | 2025 | 11847 | 1.190 |
Why?
|
| Humans | 57 | 2026 | 32284 | 1.140 |
Why?
|
| Male | 44 | 2025 | 19447 | 1.130 |
Why?
|
| Cardiology | 4 | 2017 | 104 | 1.090 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 170 | 1.080 |
Why?
|
| American Heart Association | 4 | 2017 | 92 | 1.080 |
Why?
|
| Guideline Adherence | 7 | 2018 | 109 | 1.070 |
Why?
|
| Hospitalization | 4 | 2017 | 475 | 1.050 |
Why?
|
| Registries | 10 | 2019 | 294 | 1.030 |
Why?
|
| Female | 40 | 2025 | 19953 | 1.020 |
Why?
|
| Atherosclerosis | 6 | 2022 | 826 | 1.010 |
Why?
|
| Football | 4 | 2014 | 67 | 1.000 |
Why?
|
| Hyperlipidemias | 2 | 2025 | 61 | 0.990 |
Why?
|
| Retirement | 3 | 2014 | 13 | 0.940 |
Why?
|
| Primary Prevention | 1 | 2025 | 55 | 0.900 |
Why?
|
| Cognition | 2 | 2019 | 549 | 0.890 |
Why?
|
| Aged | 25 | 2025 | 10258 | 0.840 |
Why?
|
| Risk Factors | 21 | 2019 | 3936 | 0.820 |
Why?
|
| Research Design | 1 | 2026 | 316 | 0.820 |
Why?
|
| Retinal Diseases | 1 | 2024 | 25 | 0.800 |
Why?
|
| Stroke Volume | 2 | 2017 | 417 | 0.780 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 127 | 0.780 |
Why?
|
| Adult | 21 | 2025 | 9262 | 0.770 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 427 | 0.760 |
Why?
|
| Health Status | 4 | 2017 | 356 | 0.700 |
Why?
|
| Lipoprotein(a) | 2 | 2019 | 25 | 0.700 |
Why?
|
| Intermittent Claudication | 2 | 2018 | 11 | 0.690 |
Why?
|
| Cholesterol | 3 | 2017 | 262 | 0.670 |
Why?
|
| Coronary Disease | 3 | 2016 | 226 | 0.660 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 227 | 0.640 |
Why?
|
| Cognition Disorders | 2 | 2019 | 349 | 0.590 |
Why?
|
| Apolipoproteins B | 1 | 2019 | 48 | 0.580 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 86 | 0.580 |
Why?
|
| Obesity | 4 | 2023 | 1111 | 0.580 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2016 | 20 | 0.550 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 18 | 0.550 |
Why?
|
| Time Factors | 13 | 2019 | 2203 | 0.540 |
Why?
|
| Body Mass Index | 4 | 2025 | 863 | 0.520 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 96 | 0.500 |
Why?
|
| Hospital Costs | 1 | 2017 | 48 | 0.500 |
Why?
|
| Mortality | 1 | 2017 | 122 | 0.500 |
Why?
|
| Health Status Disparities | 1 | 2018 | 128 | 0.500 |
Why?
|
| Triglycerides | 1 | 2017 | 235 | 0.490 |
Why?
|
| Forecasting | 1 | 2017 | 144 | 0.490 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 11 | 0.490 |
Why?
|
| Blood Pressure | 5 | 2020 | 866 | 0.490 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 62 | 0.490 |
Why?
|
| Peptide Fragments | 1 | 2019 | 415 | 0.490 |
Why?
|
| Primary Health Care | 3 | 2025 | 232 | 0.480 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 67 | 0.470 |
Why?
|
| Inservice Training | 1 | 2016 | 12 | 0.470 |
Why?
|
| Prospective Studies | 9 | 2019 | 2317 | 0.470 |
Why?
|
| Exercise Therapy | 1 | 2018 | 249 | 0.460 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 71 | 0.460 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 83 | 0.460 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 49 | 0.460 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 6 | 0.450 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 13 | 0.450 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.450 |
Why?
|
| Diabetes Complications | 1 | 2016 | 171 | 0.450 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 73 | 0.440 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 167 | 0.440 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 130 | 0.440 |
Why?
|
| Waist Circumference | 1 | 2014 | 91 | 0.420 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 174 | 0.420 |
Why?
|
| Comorbidity | 7 | 2017 | 563 | 0.420 |
Why?
|
| Self Efficacy | 2 | 2025 | 74 | 0.420 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 183 | 0.420 |
Why?
|
| Occupations | 1 | 2014 | 7 | 0.410 |
Why?
|
| European Continental Ancestry Group | 1 | 2018 | 1076 | 0.410 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 264 | 0.410 |
Why?
|
| Neck | 1 | 2014 | 32 | 0.410 |
Why?
|
| Athletes | 1 | 2014 | 62 | 0.410 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2019 | 79 | 0.400 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 180 | 0.400 |
Why?
|
| Nepal | 4 | 2025 | 11 | 0.370 |
Why?
|
| Treatment Outcome | 11 | 2019 | 3409 | 0.370 |
Why?
|
| Incidence | 5 | 2019 | 1243 | 0.360 |
Why?
|
| African Americans | 1 | 2018 | 1335 | 0.340 |
Why?
|
| Disease Management | 2 | 2025 | 129 | 0.320 |
Why?
|
| Lipids | 3 | 2017 | 254 | 0.310 |
Why?
|
| Cohort Studies | 5 | 2017 | 1840 | 0.310 |
Why?
|
| Prognosis | 4 | 2017 | 1529 | 0.310 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2238 | 0.310 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 14 | 0.300 |
Why?
|
| Calcinosis | 3 | 2014 | 142 | 0.300 |
Why?
|
| Stents | 3 | 2017 | 159 | 0.280 |
Why?
|
| Logistic Models | 6 | 2017 | 743 | 0.280 |
Why?
|
| Calcium | 3 | 2014 | 339 | 0.280 |
Why?
|
| Linear Models | 4 | 2017 | 426 | 0.280 |
Why?
|
| Prevalence | 6 | 2017 | 955 | 0.270 |
Why?
|
| Quality of Life | 3 | 2018 | 970 | 0.270 |
Why?
|
| Focus Groups | 2 | 2025 | 123 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 773 | 0.260 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 880 | 0.250 |
Why?
|
| Rural Population | 2 | 2025 | 216 | 0.240 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 242 | 0.240 |
Why?
|
| Postprandial Period | 2 | 2016 | 10 | 0.240 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 287 | 0.230 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 131 | 0.230 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 54 | 0.230 |
Why?
|
| Coronary Angiography | 3 | 2017 | 159 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1437 | 0.210 |
Why?
|
| Health Personnel | 1 | 2025 | 112 | 0.210 |
Why?
|
| North Carolina | 3 | 2025 | 1300 | 0.210 |
Why?
|
| Stroke | 2 | 2024 | 691 | 0.210 |
Why?
|
| Metals | 2 | 2017 | 19 | 0.210 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 9 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 161 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 650 | 0.200 |
Why?
|
| Southeastern United States | 1 | 2023 | 75 | 0.200 |
Why?
|
| Coronary Vessels | 2 | 2014 | 174 | 0.200 |
Why?
|
| Family Practice | 1 | 2023 | 49 | 0.200 |
Why?
|
| Universities | 1 | 2024 | 149 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 1484 | 0.180 |
Why?
|
| Medical History Taking | 1 | 2022 | 39 | 0.180 |
Why?
|
| Medicare | 1 | 2024 | 218 | 0.180 |
Why?
|
| Refugees | 1 | 2022 | 10 | 0.180 |
Why?
|
| Odds Ratio | 4 | 2016 | 455 | 0.170 |
Why?
|
| India | 3 | 2016 | 64 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 3899 | 0.170 |
Why?
|
| Hemorrhage | 2 | 2019 | 95 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 329 | 0.160 |
Why?
|
| Health Facilities | 1 | 2020 | 14 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 34 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2017 | 193 | 0.160 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 26 | 0.150 |
Why?
|
| Protein Precursors | 1 | 2019 | 24 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 17 | 0.150 |
Why?
|
| Models, Statistical | 2 | 2017 | 187 | 0.150 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 34 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 854 | 0.150 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 19 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 293 | 0.150 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 56 | 0.140 |
Why?
|
| Thinness | 1 | 2019 | 32 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 293 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2019 | 73 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 99 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 556 | 0.140 |
Why?
|
| Canada | 1 | 2018 | 64 | 0.140 |
Why?
|
| Transients and Migrants | 1 | 2019 | 197 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 181 | 0.130 |
Why?
|
| Coronary Restenosis | 2 | 2017 | 15 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 119 | 0.130 |
Why?
|
| Cause of Death | 1 | 2017 | 236 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2018 | 236 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 47 | 0.120 |
Why?
|
| Patient Preference | 1 | 2017 | 48 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 44 | 0.120 |
Why?
|
| Heterozygote | 1 | 2016 | 60 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 51 | 0.120 |
Why?
|
| Texas | 1 | 2016 | 41 | 0.120 |
Why?
|
| Veterans | 1 | 2016 | 64 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 59 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2017 | 567 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 66 | 0.120 |
Why?
|
| Developing Countries | 1 | 2016 | 57 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 760 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3612 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 716 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 19 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 133 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 141 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2016 | 111 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 124 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 309 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2016 | 158 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2015 | 153 | 0.110 |
Why?
|
| Alleles | 1 | 2015 | 250 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2015 | 90 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2016 | 367 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 545 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 892 | 0.110 |
Why?
|
| Anthropometry | 1 | 2014 | 89 | 0.100 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 23 | 0.100 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 59 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 365 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 31 | 0.100 |
Why?
|
| World Health Organization | 2 | 2025 | 17 | 0.100 |
Why?
|
| Apoptosis | 1 | 2015 | 375 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2016 | 329 | 0.100 |
Why?
|
| Mutation | 1 | 2015 | 497 | 0.090 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 12 | 0.090 |
Why?
|
| Young Adult | 2 | 2017 | 2651 | 0.090 |
Why?
|
| Mass Screening | 1 | 2014 | 256 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 410 | 0.090 |
Why?
|
| Inflammation | 1 | 2014 | 507 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 505 | 0.080 |
Why?
|
| Thrombosis | 1 | 2011 | 78 | 0.080 |
Why?
|
| Kansas | 1 | 2025 | 7 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2025 | 106 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2017 | 107 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2025 | 484 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 160 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 186 | 0.050 |
Why?
|
| Bhutan | 1 | 2022 | 1 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 3518 | 0.050 |
Why?
|
| Public Sector | 1 | 2020 | 2 | 0.040 |
Why?
|
| Private Sector | 1 | 2020 | 9 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2020 | 7 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 32 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 160 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 175 | 0.040 |
Why?
|
| Urban Population | 1 | 2020 | 91 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 16 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 5 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2019 | 45 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 19 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 17 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 69 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 25 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Spain | 1 | 2017 | 3 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 197 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 52 | 0.030 |
Why?
|
| Missouri | 1 | 2017 | 21 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 42 | 0.030 |
Why?
|
| Drug Costs | 1 | 2017 | 46 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 591 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 57 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 179 | 0.030 |
Why?
|
| Patient Participation | 1 | 2017 | 90 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 117 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 131 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 272 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 122 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 57 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 212 | 0.030 |
Why?
|
| Endarterectomy, Carotid | 1 | 2014 | 29 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 42 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 45 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 96 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 93 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 622 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 555 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 232 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1178 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 544 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 12 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 821 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 2012 | 9 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 141 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 69 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 47 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 34 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 57 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 286 | 0.020 |
Why?
|